JP2017533968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533968A5 JP2017533968A5 JP2017544549A JP2017544549A JP2017533968A5 JP 2017533968 A5 JP2017533968 A5 JP 2017533968A5 JP 2017544549 A JP2017544549 A JP 2017544549A JP 2017544549 A JP2017544549 A JP 2017544549A JP 2017533968 A5 JP2017533968 A5 JP 2017533968A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkylene
- membered
- compound according
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000002947 alkylene group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- -1 1,2,3,4-tetrahydronaphthalenyl Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 208000015872 Gaucher disease Diseases 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020119444A JP7519221B2 (ja) | 2014-11-06 | 2020-07-10 | 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076062P | 2014-11-06 | 2014-11-06 | |
| US62/076,062 | 2014-11-06 | ||
| PCT/US2015/059541 WO2016073895A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020119444A Division JP7519221B2 (ja) | 2014-11-06 | 2020-07-10 | 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533968A JP2017533968A (ja) | 2017-11-16 |
| JP2017533968A5 true JP2017533968A5 (enExample) | 2018-12-13 |
| JP6734860B2 JP6734860B2 (ja) | 2020-08-05 |
Family
ID=55909884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544549A Active JP6734860B2 (ja) | 2014-11-06 | 2015-11-06 | 置換ピラゾロ［１，５−ａ］ピリミジンおよび医療疾患の治療におけるその使用 |
| JP2020119444A Active JP7519221B2 (ja) | 2014-11-06 | 2020-07-10 | 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020119444A Active JP7519221B2 (ja) | 2014-11-06 | 2020-07-10 | 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10570135B2 (enExample) |
| EP (2) | EP3215511B1 (enExample) |
| JP (2) | JP6734860B2 (enExample) |
| KR (1) | KR102662215B1 (enExample) |
| CN (2) | CN107001379B (enExample) |
| AU (1) | AU2015342887B2 (enExample) |
| DK (1) | DK3215511T3 (enExample) |
| EA (1) | EA201790995A1 (enExample) |
| ES (1) | ES2984482T3 (enExample) |
| FI (1) | FI3215511T3 (enExample) |
| HR (1) | HRP20240644T1 (enExample) |
| HU (1) | HUE066864T2 (enExample) |
| IL (1) | IL252053B2 (enExample) |
| LT (1) | LT3215511T (enExample) |
| MX (1) | MX394094B (enExample) |
| PL (1) | PL3215511T3 (enExample) |
| PT (1) | PT3215511T (enExample) |
| RS (1) | RS65642B1 (enExample) |
| SI (1) | SI3215511T1 (enExample) |
| SM (1) | SMT202400187T1 (enExample) |
| WO (1) | WO2016073895A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012078855A1 (en) | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
| MX394094B (es) * | 2014-11-06 | 2025-03-24 | Bial R&D Invest S A | PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS. |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| CN108473498B (zh) | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| EP3429590A4 (en) * | 2016-03-16 | 2020-02-19 | Lysosomal Therapeutics Inc. | METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE |
| JP7046827B2 (ja) | 2016-04-06 | 2022-04-04 | リソソーマル・セラピューティクス・インコーポレイテッド | イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| JP7034935B2 (ja) * | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| CN109890829B (zh) | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
| JP7171057B2 (ja) | 2016-12-29 | 2022-11-15 | ミノリックス セラピューティクス エセ．エレ． | ヘテロアリール化合物およびその使用 |
| SG11201909735YA (en) | 2017-05-22 | 2019-11-28 | Hoffmann La Roche | Therapeutic compounds and compositions, and methods of use thereof |
| WO2019123476A1 (en) * | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| US20200339587A1 (en) * | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| US11459325B2 (en) | 2018-01-31 | 2022-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| IT201800006067A1 (it) * | 2018-06-06 | 2019-12-06 | Nuovi inibitori della diidroortato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide. | |
| AU2019360941B2 (en) | 2018-10-15 | 2025-02-27 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| CN111217816B (zh) * | 2018-11-27 | 2022-08-16 | 中国科学院上海药物研究所 | 一类flt3激酶抑制剂及其制备和应用 |
| GB202211999D0 (en) * | 2022-08-17 | 2022-09-28 | Mironid Ltd | Compounds and their use as PDE4 activators |
| WO2025198486A1 (en) | 2024-03-22 | 2025-09-25 | BIAL – R&D Investments, S.A. | Process for preparing a pyrazolo[1,5-a]pyrimidinyl carboxamide compound |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
| JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物 |
| CZ20022332A3 (cs) | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| JP4070966B2 (ja) | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
| ES2248616T3 (es) | 2001-10-22 | 2006-03-16 | Pfizer Inc. | Compuestos imidazopiridina como moduladores del receptor 5-ht4. |
| KR20040087335A (ko) | 2002-03-01 | 2004-10-13 | 야마노우치세이야쿠 가부시키가이샤 | 질소 함유 복소환 화합물 |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| CA2499494A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| EP1682134A4 (en) | 2003-11-12 | 2008-10-15 | Amicus Therapeutics Inc | GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL-AMINE DERIVATIVES FOR THE TREATMENT OF GAUCHER DISEASE |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JPWO2005077953A1 (ja) | 2004-02-18 | 2007-10-18 | 萬有製薬株式会社 | 含窒素縮合ヘテロ芳香環誘導体 |
| EP1753422B1 (en) | 2004-05-14 | 2008-05-28 | The Cleveland Clinic Foundation | Small molecule inhibitors for mrp1 and other multidrug transporters |
| JP4608542B2 (ja) | 2004-06-21 | 2011-01-12 | エフ．ホフマン−ラ ロシュ アーゲー | ピラゾロピリミジン誘導体 |
| CA2568850A1 (en) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Indolizine carboxamides and the aza and diaza derivatives thereof |
| DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| WO2006078676A2 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| BRPI0607927A2 (pt) | 2005-02-11 | 2009-10-20 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| CA2605351A1 (en) | 2005-04-21 | 2006-11-02 | Dainippon Sumitomo Pharma Co., Ltd. | N-substituted phenylacetamide derivative and pharmaceutical composition comprising the same |
| WO2006118256A1 (ja) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP5102212B2 (ja) | 2005-10-06 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
| JP5376950B2 (ja) | 2005-10-21 | 2013-12-25 | エクセリクシス， インク． | カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピリミジオン類 |
| EP1963316A2 (en) | 2005-12-08 | 2008-09-03 | Novartis AG | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| EP2040548B1 (en) | 2006-06-23 | 2012-05-02 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| WO2008019363A2 (en) | 2006-08-07 | 2008-02-14 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5ht3 modulators |
| AU2007321922A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| CA2670083A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| EP2137187A1 (en) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| EA201000003A1 (ru) | 2007-06-21 | 2010-06-30 | Айрм Ллк | Ингибиторы протеинкиназ и способы их применения |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| MX2010005950A (es) | 2007-11-28 | 2010-06-17 | Schering Corp | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. |
| US8389527B2 (en) | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| WO2009119088A1 (ja) | 2008-03-25 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2273992B1 (en) | 2008-05-01 | 2016-05-25 | Glaxosmithkline LLC | Quinolines and related analogs as sirtuin modulators |
| BRPI0920180B1 (pt) | 2008-10-14 | 2021-10-26 | Entasis Therapeutics Limited | Compostos herecíclicos substituídos, uso dos mesmos e composiçâo farmacêutica compreendendo os ditos compostos |
| EP2962566A1 (en) * | 2008-10-31 | 2016-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PE20170003A1 (es) | 2009-08-17 | 2017-03-15 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| EP2593457B1 (en) * | 2010-07-13 | 2017-08-23 | F. Hoffmann-La Roche AG | Pyrazolo[1,5a]pyrimidine and thieno[3,2b]pyrimidine derivatives as irak4 modulators |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| WO2012078855A1 (en) * | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| EP2688872A4 (en) * | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| JP6061922B2 (ja) | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
| CN103857657B (zh) | 2011-08-18 | 2016-04-20 | 日本新药株式会社 | 杂环衍生物及医药 |
| JP6054967B2 (ja) | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アネレート化ピリミジンおよびその使用 |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| AU2012325909B2 (en) | 2011-10-20 | 2016-06-09 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| JP2015503519A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| US9340549B2 (en) * | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| US8969565B2 (en) | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| WO2013134336A2 (en) | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| WO2013148333A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
| BR112014029404A2 (pt) | 2012-05-31 | 2017-06-27 | Hoffmann La Roche | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção |
| EP2865671B1 (en) | 2012-06-22 | 2017-11-01 | Sumitomo Chemical Company, Ltd | Fused heterocyclic compound |
| WO2014025651A1 (en) * | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
| JP2015532650A (ja) | 2012-09-05 | 2015-11-12 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 非生物的植物ストレスに対する活性物質としての置換された２−アミドベンズイミダゾール類、２−アミドベンゾオキサゾール類および２−アミドベンゾチアゾール類またはそれらの塩の使用 |
| JP6377068B2 (ja) | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| DK3418281T3 (da) * | 2012-12-07 | 2020-12-07 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme |
| KR20140086002A (ko) | 2012-12-28 | 2014-07-08 | 한미약품 주식회사 | Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체 |
| WO2014141129A2 (en) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| US20160159808A1 (en) | 2013-07-24 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015026574A1 (en) | 2013-08-20 | 2015-02-26 | Bristol-Myers Squibb Company | Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia |
| MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
| AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2015147639A1 (en) | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| MX394094B (es) | 2014-11-06 | 2025-03-24 | Bial R&D Invest S A | PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS. |
| EP3317265A4 (en) | 2015-07-01 | 2019-04-17 | Northwestern University | SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY |
| JP2018522872A (ja) | 2015-07-01 | 2018-08-16 | ノースウェスタン ユニバーシティ | 置換４−メチルピロロ［１，２−ａ］ピリミジン−８−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017040877A1 (en) | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| TWI824309B (zh) | 2015-11-06 | 2023-12-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
| JP6843135B2 (ja) | 2015-11-18 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| CN108473501B (zh) | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 治疗化合物、其组合物及使用方法 |
| JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| JP7046827B2 (ja) | 2016-04-06 | 2022-04-04 | リソソーマル・セラピューティクス・インコーポレイテッド | イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| EP3452045A1 (en) | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| WO2017192929A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US20200339587A1 (en) | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
-
2015
- 2015-11-06 MX MX2017005940A patent/MX394094B/es unknown
- 2015-11-06 CN CN201580068129.9A patent/CN107001379B/zh active Active
- 2015-11-06 WO PCT/US2015/059541 patent/WO2016073895A1/en not_active Ceased
- 2015-11-06 IL IL252053A patent/IL252053B2/en unknown
- 2015-11-06 PT PT158575084T patent/PT3215511T/pt unknown
- 2015-11-06 RS RS20240536A patent/RS65642B1/sr unknown
- 2015-11-06 LT LTEPPCT/US2015/059541T patent/LT3215511T/lt unknown
- 2015-11-06 CN CN202211277924.7A patent/CN115925711A/zh active Pending
- 2015-11-06 HU HUE15857508A patent/HUE066864T2/hu unknown
- 2015-11-06 FI FIEP15857508.4T patent/FI3215511T3/fi active
- 2015-11-06 EP EP15857508.4A patent/EP3215511B1/en active Active
- 2015-11-06 SI SI201532014T patent/SI3215511T1/sl unknown
- 2015-11-06 EP EP24166780.7A patent/EP4406616A3/en not_active Withdrawn
- 2015-11-06 US US15/523,769 patent/US10570135B2/en active Active
- 2015-11-06 ES ES15857508T patent/ES2984482T3/es active Active
- 2015-11-06 HR HRP20240644TT patent/HRP20240644T1/hr unknown
- 2015-11-06 PL PL15857508.4T patent/PL3215511T3/pl unknown
- 2015-11-06 AU AU2015342887A patent/AU2015342887B2/en active Active
- 2015-11-06 DK DK15857508.4T patent/DK3215511T3/da active
- 2015-11-06 EA EA201790995A patent/EA201790995A1/ru unknown
- 2015-11-06 JP JP2017544549A patent/JP6734860B2/ja active Active
- 2015-11-06 SM SM20240187T patent/SMT202400187T1/it unknown
- 2015-11-06 KR KR1020177015300A patent/KR102662215B1/ko active Active
-
2017
- 2017-02-23 US US15/440,107 patent/US9732089B2/en active Active
-
2020
- 2020-01-03 US US16/733,598 patent/US11091492B2/en active Active
- 2020-07-10 JP JP2020119444A patent/JP7519221B2/ja active Active
-
2021
- 2021-07-07 US US17/369,507 patent/US11932645B2/en active Active
-
2024
- 2024-02-09 US US18/437,558 patent/US20250066364A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533968A5 (enExample) | ||
| JP2020183410A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2014521688A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2017537949A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2011500758A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2014506907A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| JP2016505637A5 (enExample) | ||
| JP2014510147A5 (enExample) |